Answers are grounded in this paper and cite their sources.
This reduction was equally observed among patients with and without type 2 diabetes However, these CV benefits were demonstrated in stable outpatients with chronic heart failure. It is not known whether initiation of SGLT2 inhibitors in hospitalized patients with acute heart failure will result in similar favorable outcomes. Moreover, the safety of use of SGLT2 inhibitors in the hospital setting in general is not well studied. The
No takes yet. Share an insight, caveat, or question.
Nasser Mikhai (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: